MedTrace Logo

In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects

NCT05429775 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-06-23

No results posted yet for this study

Summary

This is a single centre, open-label, sequential, single dose 4-period crossover, scintigraphic imaging study in healthy male and non-pregnant, non-lactating female subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Budesonide

single dose of 2 mg oral suspension formulation administered orally under fasting conditions

Sponsors & Collaborators

Principal Investigators

  • Sandoz · Sandoz

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-26
Primary Completion
2019-01-29
Completion
2019-01-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429775 on ClinicalTrials.gov